• Je něco špatně v tomto záznamu ?

Organoids as a personalized medicine tool for ultra-rare mutations in cystic fibrosis: The case of S955P and 1717-2A>G

IAL. Silva, T. Doušová, S. Ramalho, R. Centeio, LA. Clarke, V. Railean, HM. Botelho, A. Holubová, I. Valášková, JT. Yeh, TC. Hwang, CM. Farinha, K. Kunzelmann, MD. Amaral,

. 2020 ; 1866 (11) : 165905. [pub] 20200728

Jazyk angličtina Země Nizozemsko

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc20027668

Grantová podpora
R01 DK055835 NIDDK NIH HHS - United States

BACKGROUND: For most of the >2000 CFTR gene variants reported, neither the associated disease liability nor the underlying basic defect are known, and yet these are essential for disease prognosis and CFTR-based therapeutics. Here we aimed to characterize two ultra-rare mutations - 1717-2A > G (c.1585-2A > G) and S955P (p.Ser955Pro) - as case studies for personalized medicine. METHODS: Patient-derived rectal biopsies and intestinal organoids from two individuals with each of these mutations and F508del (p.Phe508del) in the other allele were used to assess CFTR function, response to modulators and RNA splicing pattern. In parallel, we used cellular models to further characterize S955P independently of F508del and to assess its response to CFTR modulators. RESULTS: Results in both rectal biopsies and intestinal organoids from both patients evidence residual CFTR function. Further characterization shows that 1717-2A > G leads to alternative splicing generating <1% normal CFTR mRNA and that S955P affects CFTR gating. Finally, studies in organoids predict that both patients are responders to VX-770 alone and even more to VX-770 combined with VX-809 or VX-661, although to different levels. CONCLUSION: This study demonstrates the high potential of personalized medicine through theranostics to extend the label of approved drugs to patients with rare mutations.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20027668
003      
CZ-PrNML
005      
20210114152217.0
007      
ta
008      
210105s2020 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.bbadis.2020.165905 $2 doi
035    __
$a (PubMed)32730979
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Silva, Iris A L $u University of Lisboa, Faculty of Sciences, BioISI - Biosystems & Integrative Sciences Institute, Campo Grande, C8 bdg, 1749-016 Lisboa, Portugal.
245    10
$a Organoids as a personalized medicine tool for ultra-rare mutations in cystic fibrosis: The case of S955P and 1717-2A>G / $c IAL. Silva, T. Doušová, S. Ramalho, R. Centeio, LA. Clarke, V. Railean, HM. Botelho, A. Holubová, I. Valášková, JT. Yeh, TC. Hwang, CM. Farinha, K. Kunzelmann, MD. Amaral,
520    9_
$a BACKGROUND: For most of the >2000 CFTR gene variants reported, neither the associated disease liability nor the underlying basic defect are known, and yet these are essential for disease prognosis and CFTR-based therapeutics. Here we aimed to characterize two ultra-rare mutations - 1717-2A > G (c.1585-2A > G) and S955P (p.Ser955Pro) - as case studies for personalized medicine. METHODS: Patient-derived rectal biopsies and intestinal organoids from two individuals with each of these mutations and F508del (p.Phe508del) in the other allele were used to assess CFTR function, response to modulators and RNA splicing pattern. In parallel, we used cellular models to further characterize S955P independently of F508del and to assess its response to CFTR modulators. RESULTS: Results in both rectal biopsies and intestinal organoids from both patients evidence residual CFTR function. Further characterization shows that 1717-2A > G leads to alternative splicing generating <1% normal CFTR mRNA and that S955P affects CFTR gating. Finally, studies in organoids predict that both patients are responders to VX-770 alone and even more to VX-770 combined with VX-809 or VX-661, although to different levels. CONCLUSION: This study demonstrates the high potential of personalized medicine through theranostics to extend the label of approved drugs to patients with rare mutations.
650    _2
$a alely $7 D000483
650    _2
$a aminofenoly $x terapeutické užití $7 D000627
650    _2
$a aminopyridiny $x terapeutické užití $7 D000631
650    _2
$a benzodioxoly $x terapeutické užití $7 D052117
650    _2
$a western blotting $7 D015153
650    _2
$a cystická fibróza $x farmakoterapie $x genetika $7 D003550
650    _2
$a protein CFTR $x genetika $x metabolismus $7 D019005
650    _2
$a elektrofyziologie $7 D004594
650    _2
$a fluorescenční protilátková technika $7 D005455
650    _2
$a genotyp $7 D005838
650    _2
$a lidé $7 D006801
650    _2
$a indoly $x terapeutické užití $7 D007211
650    _2
$a mutace $x genetika $7 D009154
650    _2
$a individualizovaná medicína $x metody $7 D057285
650    _2
$a chinolony $x terapeutické užití $7 D015363
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Doušová, Tereza $u Department of Pediatrics, 2nd Faculty of Medicine, Charles University and University Hospital Motol, V Uvalu 84,Prague 5, 150 06 Prague, Czech Republic.
700    1_
$a Ramalho, Sofia $u University of Lisboa, Faculty of Sciences, BioISI - Biosystems & Integrative Sciences Institute, Campo Grande, C8 bdg, 1749-016 Lisboa, Portugal.
700    1_
$a Centeio, Raquel $u University of Lisboa, Faculty of Sciences, BioISI - Biosystems & Integrative Sciences Institute, Campo Grande, C8 bdg, 1749-016 Lisboa, Portugal.
700    1_
$a Clarke, Luka A $u University of Lisboa, Faculty of Sciences, BioISI - Biosystems & Integrative Sciences Institute, Campo Grande, C8 bdg, 1749-016 Lisboa, Portugal.
700    1_
$a Railean, Violeta $u University of Lisboa, Faculty of Sciences, BioISI - Biosystems & Integrative Sciences Institute, Campo Grande, C8 bdg, 1749-016 Lisboa, Portugal.
700    1_
$a Botelho, Hugo M $u University of Lisboa, Faculty of Sciences, BioISI - Biosystems & Integrative Sciences Institute, Campo Grande, C8 bdg, 1749-016 Lisboa, Portugal.
700    1_
$a Holubová, Andrea $u Department of Biology and Medical Genetics, 2nd Faculty of Medicine, Charles University and University Hospital Motol, V Uvalu 84,Prague 5, 150 06 Prague, Czech Republic.
700    1_
$a Valášková, Iveta $u Department of Medical Genetics, Masaryk University Brno and University Hospital Brno, Jihlavská 20, Brno 625 00, Czech Republic.
700    1_
$a Yeh, Jiunn-Tyng $u Dalton Cardiovascular Research Center, University of Missouri, Columbia, MO, United States of America.
700    1_
$a Hwang, Tzyh-Chang $u Dalton Cardiovascular Research Center, University of Missouri, Columbia, MO, United States of America.
700    1_
$a Farinha, Carlos M $u University of Lisboa, Faculty of Sciences, BioISI - Biosystems & Integrative Sciences Institute, Campo Grande, C8 bdg, 1749-016 Lisboa, Portugal.
700    1_
$a Kunzelmann, Karl $u Institut für Physiologie, Universität Regensburg, Universitätsstraße 31, D-93053 Regensburg, Germany.
700    1_
$a Amaral, Margarida D $u University of Lisboa, Faculty of Sciences, BioISI - Biosystems & Integrative Sciences Institute, Campo Grande, C8 bdg, 1749-016 Lisboa, Portugal. Electronic address: mdamaral@fc.ul.pt.
773    0_
$w MED00000539 $t Biochimica et biophysica acta. Molecular basis of disease $x 1879-260X $g Roč. 1866, č. 11 (2020), s. 165905
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32730979 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20210105 $b ABA008
991    __
$a 20210114152215 $b ABA008
999    __
$a ok $b bmc $g 1608003 $s 1118848
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 1866 $c 11 $d 165905 $e 20200728 $i 1879-260X $m Biochimica et biophysica acta. Molecular basis of disease $n Biochim Biophys Acta $x MED00000539
GRA    __
$a R01 DK055835 $p NIDDK NIH HHS $2 United States
LZP    __
$a Pubmed-20210105

Najít záznam

Citační ukazatele

    Možnosti archivace